newsfilter
← Latest News
PR Newswire·

Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates

AZTR
  • Azitra reported Q1 2026 financial results & provided a business update as of May 13, 2026.
  • Added MD Anderson Cancer Center as a clinical site for the Phase 1/2 trial of ATR-04 targeting EGFRi-associated skin rash.
  • Launched a cosmeceutical initiative using proprietary filaggrin technologies to address fine lines, wrinkles, dry skin, & eczema-like rashes.
  • Secured a new U.S. patent covering ATR-12, the lead candidate for Netherton syndrome.
  • Announced a poster presentation at ASGCT 2026 highlighting ATR-01 preclinical data & the engineered live biotherapeutic platform.
  • Priced a private placement financing of up to approximately $10.5 million, with an additional $20.9 million potential upon warrant exercise.
  • ATR-COSF consumer initiative expects synthesized ingredient results mid-2026 & human application studies in Q3 2026.
  • ATR-12 Phase 1b trial for Netherton syndrome reported safety data in June 2025, with topline data anticipated in H2 2026.
  • ATR-04 Phase 1/2 trial dosed the first patient in Q3 2025, with first cohort topline data expected in H2 2026.
  • ATR-01 for Ichthyosis Vulgaris reported positive preclinical data in Q3 2025, with IND-enabling studies continuing in 2026.
  • R&D expenses were $1.6 million for Q1 2026, compared to $1.3 million in the prior year period.
  • G&A expenses were $2.4 million for Q1 2026, compared to $1.9 million in the prior year period.
  • Net loss was $3.9 million for Q1 2026, compared to $3.1 million in the comparable 2025 period.
  • Cash & cash equivalents totaled $10.1 million as of March 31, 2026.
  • Total operating expenses reached $3.93 million, with total assets increasing to $12.13 million.
  • Net loss per share was $0.25, with weighted average common stock outstanding at 15.5 million shares.